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Background:  The prevalence of Fabry disease (FD) in left ventricular hypertrophy (LVH) patients has been reported as approximately 
1 to 3 percent. Because Fabry disease has nonspecific, multi-organ manifestations and due to its rarity, the prevalence of FD may be 
underestimated. We investigated the prevalence of cardiac Fabry disease in Korean hypertrophic cardiomyopathy (HCM) patients and 
made a new screening criteria.
methods: We consecutively performed cardiac FD screening using α-galactosidase A enzyme activity assay and mutation analysis of the 
alpha-Gal A gene on patients with newly diagnosed HCM who fulfilled at least one of the newly-invented screening criteria at our institution 
from March 2012 to August 2014. The new criteria consist of 1) atypical HCM defined as diffuse, symmetric mid-ventricular, biventricular, 
or predominant left ventricular (LV) free wall hypertrophy >13mm thickness 2) arrhythmia including atrial tachycardia, atrial fibrillation, 
ventricular tachycardia, symptomatic premature ventricular complex, or high degree atrioventricular (AV) block 3) short PR interval defined 
as < 120ms on ECG, and 4) symptoms of autonomic dysfunction including unexplained syncope, orthostatic hypotension, dizziness, or 
chronotrophic incompetence.
results: Upon application of our screening criteria, 67 newly diagnosed HCM patients (mean age;44.1 ± 1.8, 37 males) fulfilled at least 
one out of the four criteria; 34 subjects had just one applicable criterion, 17 subjects fulfilled two, and 16 subjects fulfilled three out of the 
four criteria. From this screening, three unrelated patients (4.5%, 2 female and 1 male) were newly diagnosed with cardiac FD and all of 
them had three out of the four criteria fulfilled. The positive predictive value of this new screening criteria in HCM patients was 18.75% (3 
out of 16 patients).
conclusion:  Fabry disease is not an extremely rare disease in the Korean HCM population. New screening criteria is useful for the 
detection of cardiac FD in patients with HCM. It is necessary to conduct cardiac Fabry disease screening on HCM patients who satisfy 
three out of the four of our criteria, as it could aid in early detection of cardiac FD.
